[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announces it purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,963,475,311 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,959,595,106 ordinary shares with voting rights. A full breakdown of the individual trades is provided via the linked RNS PDF and will also be available on the Company's investor website. The announcement clarifies it does not constitute an offer for securities.

Positive

• Share buyback executed: Purchase of 2,875,831 ordinary shares completed for cancellation under the second tranche of the programme
• Updated share counts provided: Registered share capital, treasury shares, and voting shares are disclosed to inform shareholder notification obligations
• Trade-level transparency: Full breakdown of individual trades made available via RNS PDF and the Company website

Negative

• None.

Insights

Corporate Finance Analyst

TL;DR: Company executed a share buyback cancellation of 2,875,831 shares and updated its issued and voting share totals.

Haleon completed purchases of 2,875,831 ordinary shares for cancellation as part of the second tranche of a previously announced buyback programme. The filing reports updated registered share capital and the number of treasury shares, and provides a link to a full trade breakdown. The disclosure is routine and compliant with market abuse rules, supplying necessary figures shareholders use to assess notification thresholds under the FCA's rules.

Corporate Governance Expert

TL;DR: Formal notification of share cancellation and updated share counts ensures transparency for shareholder reporting obligations.

The company furnishes the transaction details required by Article 5(1)(b) of the Market Abuse Regulation and states where the trade-level data can be accessed. The filing updates the official share register counts and clarifies the number of voting shares, which is material for shareholders determining notification requirements under the FCA Disclosure Guidance and Transparency Rules.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	28 August 2025 - Transaction in Own Shares

99.1

Haleon plc: Transaction in own shares

28 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,875,831 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	27 August 2025	27 August 2025	27 August 2025
Number of Shares purchased:	2,875,831	-	-
Highest price paid per Share (p):	363.7000	-	-
Lowest price paid per Share (p):	359.2000	-	-
Volume weighted average price paid per Share (p):	361.3796	-	-

Following the settlement of the above, the Company's registered share capital is 8,963,475,311 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,959,595,106 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/9460W_1-2025-8-27.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 28, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLN) purchase in this announcement?

Haleon purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its buyback programme.

How many ordinary shares with voting rights does Haleon have after this transaction?

After settlement, there are 8,959,595,106 ordinary shares with voting rights.

How many treasury shares does Haleon hold following the cancellation?

The Company holds 3,880,205 shares as treasury shares.

Where can I find the full breakdown of the individual trades?

A full breakdown is available at the provided RNS PDF link and on the Company's investor website: www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement states it does not constitute, or form part of, an offer or solicitation for securities in any jurisdiction.